Scroll to top

Scroll to top

News Releases

News Releases

Month Year

Month Year

Investor Alerts

May 13, 2020

Immunic, Inc. Receives First Regulatory Approval from German Health Authority BfArM to Initiate a Phase 2 Clinical Trial of its Selective Oral DHODH Inhibitor, IMU-838, in COVID-19 Patients
May 8, 2020

Immunic, Inc. Reports First Quarter 2020 Financial Results and Highlights Recent Activity
Apr 23, 2020

Immunic, Inc. Announces Pricing of $15 Million Financing
Apr 21, 2020

Immunic, Inc. Reports that IMU-838, a Selective Oral DHODH Inhibitor, Has Demonstrated Preclinical Activity Against SARS-CoV-2 and Explores Plans for a Phase 2 Clinical Trial in COVID-19 Patients

- In Cellular Assays with SARS-CoV-2 Clinical Isolates, IMU-838 Shows Ability to Inhibit Viral Replication of SARS-CoV-2 -
Apr 17, 2020

Immunic, Inc. Announces Changes to Executive Team
Mar 16, 2020

Immunic, Inc. Reports Year End 2019 Financial Results and Highlights Recent Achievements

- Top-Line Data from Phase 2 EMPhASIS Trial in Relapsing-Remitting Multiple Sclerosis Expected in Third Quarter 2020 -
Feb 11, 2020

Immunic, Inc. to Participate in Scientific and Investor Conferences in February
Jan 8, 2020

Immunic Exercises its Option for the Exclusive Worldwide License to IMU-856 from Daiichi Sankyo Co., Ltd.

Phase 1 Clinical Studies to begin in First Half of 2020
Dec 4, 2019

Immunic, Inc. to Present Data on IMU-856, for the First Time, at the Crohn's and Colitis Foundation's IBD Innovate Conference

IMU-856 has the potential to address one of the putative root causes of inflammatory bowel disease without impairing the immune system
Nov 25, 2019

Immunic, Inc. to Participate in Investor and Scientific Conferences in December

Show per page